Loading...
•
Sep 29, 2023
Novanta Q3 2023 Earnings Report
Novanta reported strong Q3 2023 results with margin, profit, and cash flow at or above expectations, driven by growth in medical end-markets.
Key Takeaways
Novanta's Q3 2023 revenue was $221.5 million, a slight decrease of 0.7% year-over-year. GAAP net income reached $21.2 million, with diluted EPS at $0.59. Adjusted EBITDA stood at $52.2 million, and operating cash flow was $44.6 million.
GAAP revenue was $221.5 million, a 0.7% decrease compared to Q3 2022.
GAAP net income was $21.2 million, compared to $22.5 million in Q3 2022.
Adjusted EBITDA was $52.2 million, compared to $49.4 million in Q3 2022.
Operating cash flow was $44.6 million, compared to $14.8 million in Q3 2022.
Revenue by Segment
Forward Guidance
For Q4 2023, Novanta expects GAAP revenue between $208 million and $212 million, Adjusted EBITDA between $42 million and $45 million, and Adjusted Diluted EPS between $0.59 and $0.66. For the full year 2023, the Company expects GAAP revenue of approximately $878 million to $882 million, Adjusted Gross Profit Margin to be approximately 46.6% to 46.8%, Adjusted EBITDA to be in the range of $193 million to $196 million and Adjusted Diluted EPS to be in the range of $2.98 to $3.05.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...